Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung CancerYukihiro Toi, Yoshihiro Honda, Yutaka Domeki et al.|JAMA Oncology|2018Cited by 370
Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with NivolumabYukihiro Toi, Yoshihiro Honda, Jun Sugisaka et al.|The Oncologist|2018Cited by 296
Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung CancerMari Aso, Shunichi Sugawara, Yukihiro Toi et al.|The Oncologist|2019Cited by 59
Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with PembrolizumabJun Sugisaka, Shunichi Sugawara, Yukihiro Toi et al.|JMA Journal|2019Cited by 26
Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancerKana Ono, Shunichi Sugawara, Hirotaka Ono et al.|Cancer Medicine|2021Cited by 19